Design of a study of semaglutide in psychiatry, with Roger S. McIntyre, MD

Roger S. McIntyre, MD: GLP-1 agonists for psychiatry?

Although their clinical benefit for cardiometabolic, renal, hepatic, and obesity medicine may seem too good to be true, the GLP-1 and GIP receptor agonist incretin therapy drug classes are proving …

Read more

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat Patients with MASH in Phase IIb Study

Business Wire

RAMAT GAN, Israel, May 9, 2024–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a portfolio of proprietary small molecule drugs that treat oncology and inflammatory diseases, …

Read more